$187 Million is the total value of Prosight Management, LP's 38 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | New | HORIZON THERAPEUTICS PUB L | $18,753,000 | – | 303,000 | +100.0% | 10.05% | – |
| ALKS | New | ALKERMES PLC | $11,213,000 | – | 502,150 | +100.0% | 6.01% | – |
| HUM | New | HUMANA INC | $6,210,000 | – | 12,800 | +100.0% | 3.33% | – |
| JNJ | New | JOHNSON & JOHNSON | $5,179,000 | – | 31,704 | +100.0% | 2.78% | – |
| New | PROTHENA CORP PLCcall | $3,219,000 | – | 53,100 | +100.0% | 1.72% | – | |
| ORIC | New | ORIC PHARMACEUTICALS INC | $2,996,000 | – | 936,334 | +100.0% | 1.60% | – |
| INCY | New | INCYTE CORP | $2,696,000 | – | 40,450 | +100.0% | 1.44% | – |
| OMCL | New | OMNICELL COM | $2,672,000 | – | 30,700 | +100.0% | 1.43% | – |
| AVTR | New | AVANTOR INC | $2,404,000 | – | 122,668 | +100.0% | 1.29% | – |
| BAX | New | BAXTER INTL INC | $2,101,000 | – | 39,000 | +100.0% | 1.13% | – |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $1,960,000 | – | 80,000 | +100.0% | 1.05% | – |
| New | CASSAVA SCIENCES INCput | $1,501,000 | – | 35,900 | +100.0% | 0.80% | – | |
| EOLS | New | EVOLUS INC | $1,290,000 | – | 160,200 | +100.0% | 0.69% | – |
| ADCT | New | ADC THERAPEUTICS SA | $1,194,000 | – | 247,630 | +100.0% | 0.64% | – |
| GRPH | New | GRAPHITE BIO INC | $1,130,000 | – | 356,445 | +100.0% | 0.60% | – |
| ABCL | New | ABCELLERA BIOLOGICS INC | $856,000 | – | 86,504 | +100.0% | 0.46% | – |
| New | R1 RCM INC | $595,000 | – | 32,113 | +100.0% | 0.32% | – | |
| SPOK | New | SPOK HLDGS INC | $497,000 | – | 65,000 | +100.0% | 0.27% | – |
| MRVI | New | MARAVAI LIFESCIENCES HLDGS I | $218,000 | – | 8,540 | +100.0% | 0.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.